Aurobindo Pharma receives approval from the U.S. Food and Drug Administration (USFDA) for a generic inhalation aerosol metered-dose inhaler (MDI) used to treat asthma patients. The approval is described as the company’s first MDI, marking an expansion into more complex respiratory therapies.
Both reports highlight that the USFDA action adds to Aurobindo’s track record of ANDA authorizations. One outlet notes it as a milestone for the company’s respiratory portfolio, while another frames the development in terms of the company’s cumulative approvals. NDTV specifically says the approval increases Aurobindo’s total ANDA approvals to 596, reinforcing its broader generics pipeline. Business Line emphasizes the significance of the MDI milestone itself and its role in building experience with inhalation products.
The coverage is largely aligned on the regulatory approval and the product category, with differences mainly in emphasis—either the strategic milestone of entering the MDI segment or the updated count of overall ANDA approvals.
